[1] Gao MS, Chen YJ.Risk analysis of the application of proton pump inhibitors[J]. Chinese General Practice(中国全科医学), 2015, 18(20): 2448-2450. [2] Li MH, Feng Q,Li XY, et al.Research progress of clinical applications and adverse reactions of lansoprazole[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(12): 729-731. [3] Li M, Su X,Shan YY.Analysis of application reasonability of proton pump inhibitors in hospital intensive care units[J].Northwest Pharmaceutical Journal(西北药学杂志), 2018,33(6): 837-840. [4] Verhaegh F,Masclee AA.High risk of drug-induced microscopic colitis with concomitant use of NSAIDS and proton pump inhibitors[J].Annals of Pharmacotherapy,2016,43(9):1004-1013. [5] Ernest HL, Melissa B, Hunglaw YT, et al.Association between proton pump inhibitors and microscopic colitis:implications for practice and future research[J].Alimentary Pharmacology Therapeutics, 2017, 51(3):253-263. [6] Lu YX, Li ZJ.Microscopic colitis: a cause of diarrhea easy to miss[J].New Medicine(新医学), 2014, 45(4): 226-230. [7] Xu XM, Huang GM.Advances in study on treatment of microscopic colitis[J]. Chinese Journal of Gastroenterology(胃肠病学) , 2015, 20(1): 45-48. [8] Zhao XT, Wang MC.Relationship between proton pump inhibitor and clostridium difficile infection[J]. Medical Recapitulate(医学综述), 2018, 24(8): 1530-1534. [9] Xie TT, Guo DH, Zhao SY, et al.Analysis of 1298 cases of adverse drug reactions induced by proton pump inhibitors in military hospitals[J].Pharmac-eutical Care and Research(药学服务与研究), 2018, 18(3): 173-176. [10] Zhang YJ, Guo SG, Fang J, et al.Rational usage of proton pump inhibitors in inpatients in a hospital[J]. China Pharmaceuticals(中国药业), 2017, 26(21): 82-84. [11] Liang YH, Hou YM, Huang L.Analysis of proton pump inhibitors application in a tumor hospital from 2013 to 2015[J]. Northwest Pharmaceutical Journal(西北药学杂志), 2017, 32(3): 385-387. [12] Li HY, Hu B.Pharmaceutical care practice of proton pump inhibitors and its interactions with other drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒) , 2016, 13(7): 429-432. |